Key Developments: Organovo Holdings Inc (ONVO.A)

ONVO.A on American Stock Exchange

6.36USD
1:55pm EST
Price Change (% chg)

$-0.21 (-3.20%)
Prev Close
$6.57
Open
$6.69
Day's High
$6.69
Day's Low
$6.30
Volume
70,143
Avg. Vol
98,246
52-wk High
$12.38
52-wk Low
$5.13

Search Stocks

Latest Key Developments (Source: Significant Developments)

Organovo Holdings Inc Closes $46.6 Million Public Offering Of Common Stock And Exercise Of Over-Allotment Option
Wednesday, 7 Aug 2013 04:05pm EDT 

Organovo Holdings Inc announced the closing of its previously announced underwritten public offering of 9,000,000 shares of its common stock, as well as 1,350,000 additional shares of its common stock pursuant to the full exercise of the over-allotment option granted to the underwriters. The shares were sold at the public offering price of $4.50 per share and the company estimates the aggregate net proceeds to the Company will be approximately $43.3 million, after deducting underwriting discounts and commissions and other estimated offering expenses. Lazard Capital Markets LLC and Oppenheimer & Co. Inc. acted as joint book-runners for the offering. JMP Securities LLC and Maxim Group LLC served as co-managers for the offering.  Full Article

Organovo Holdings Inc Prices $40.5 Million Public Offering of Common Stock
Friday, 2 Aug 2013 09:18am EDT 

Organovo Holdings Inc announced the sale of 9,000,000 shares of its common stock in an underwritten public offering at a price to the public of $4.50 per share. The net offering proceeds to Organovo from the sale of the shares are expected to be approximately $37.7 million, after deducting underwriting discounts and commissions and other estimated offering expenses, but excluding any exercise of the underwriters' over-allotment option. The Company anticipates using the net proceeds from this offering for general corporate purposes, including research and development, the development and commercialization of its products, general administrative expenses, license or technology acquisitions, and working capital and capital expenditures. The offering is expected to close on or about August 7, 2013, subject to customary closing conditions. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 1,350,000 shares of common stock on the same terms and conditions, solely to cover over-allotments, if any. Lazard Capital Markets LLC and Oppenheimer & Co. Inc. are acting as joint book-runners for the offering. JMP Securities LLC and Maxim Securities LLC are each acting as co-managers for the offering.  Full Article

Organovo Holdings Inc Proposes Public Offering of Common Stock
Thursday, 1 Aug 2013 04:01pm EDT 

Organovo Holdings Inc announced that it intends to offer and sell shares of its common stock in an underwritten public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Organovo also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering to cover over-allotments, if any. All of the shares in the offering are to be sold by Organovo. Lazard Capital Markets LLC and Oppenheimer & Co. Inc. are acting as joint book-runners for the offering.  Full Article

Organovo Holdings Inc To List Common Stock On New York Stock Exchange MKT
Tuesday, 9 Jul 2013 08:05am EDT 

Organovo Holdings Inc announced that its common shares have been approved to list on the NYSE MKT and will begin trading on the New York Stock Exchange on July 11, 2013. The Company will continue to trade under the symbol "ONVO" but will withdraw its shares from listing on the OTC QX concurrent with listing its shares on the NYSE MKT, the premier US equities market for listing and trading of small growth companies.  Full Article

Organovo Holdings Inc Announces Change Of Fiscal Year
Wednesday, 3 Apr 2013 08:05am EDT 

Organovo Holdings Inc announced that the Company's Board of Directors has approved a fiscal year-end change from December 31 to March 31, beginning on March 31, 2013. With this change, Organovo's current fiscal year began on April 1 and will end on March 31 each year. The change in fiscal year is in alignment with the Company's intention to apply for an initial listing on the NYSE or NASDAQ at the earliest available opportunity. The Company expects to file a transition report for the three-month transition period of January 1, 2013 to March 31, 2013 on Form 10-K on or about May 31, 2013.  Full Article

Search Stocks